Spyre Therapeutics Inc logo

Spyre Therapeutics Inc

NAS:SYRE (USA)  
$ 37.93 +0.93 (+2.51%) 04:00 PM EST
At Loss
Volume:
951.53K
Avg Vol (2M):
570.97K
Volume:
951.53K
At Loss
Avg Vol (2M):
570.97K

Business Description

Description
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Name Current Vs Industry Vs History
Cash-To-Debt 78.34
Equity-to-Asset 0.54
Debt-to-Equity 0.02
Debt-to-EBITDA -0.03
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.23
Distress
Grey
Safe
Beneish M-Score -5
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 21.1
3-Year EPS without NRI Growth Rate 18.6
3-Year FCF Growth Rate 27.2
Name Current Vs Industry Vs History
5-Day RSI 34.8
9-Day RSI 47.07
14-Day RSI 53.07
6-1 Month Momentum % 116.8
12-1 Month Momentum % 226.58

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 10.68
Quick Ratio 10.68
Cash Ratio 10.61
Days Sales Outstanding 145.22

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -165.9
Shareholder Yield % 0.03
Name Current Vs Industry Vs History
Operating Margin % -14510.61
Net Margin % -38238.15
FCF Margin % -11276.52
ROA % -184.88
ROIC % -269.44
ROC (Joel Greenblatt) % -2262.95
ROCE % -110.86

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 159.35
EV-to-EBIT -9.2
EV-to-EBITDA -9.27
EV-to-Revenue 1335.48
EV-to-Forward-Revenue 18.54
EV-to-FCF -11.84
Price-to-Net-Cash 7.54
Earnings Yield (Greenblatt) % -10.87
FCF Yield % -7.29

Financials (Next Earnings Date:2024-05-10 Est.)

SYRE's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:SYRE

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Spyre Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.886
EPS (TTM) ($) -72.842
Beta 3.6
Volatility % 262.61
14-Day RSI 53.07
14-Day ATR ($) 3.510207
20-Day SMA ($) 38.719
12-1 Month Momentum % 226.58
52-Week Range ($) 2.66 - 47.97
Shares Outstanding (Mil) 36.15

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Spyre Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Spyre Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Spyre Therapeutics Inc Frequently Asked Questions

What is Spyre Therapeutics Inc(SYRE)'s stock price today?
The current price of SYRE is $37.93. The 52 week high of SYRE is $47.97 and 52 week low is $2.66.
When is next earnings date of Spyre Therapeutics Inc(SYRE)?
The next earnings date of Spyre Therapeutics Inc(SYRE) is 2024-05-10 Est..
Does Spyre Therapeutics Inc(SYRE) pay dividends? If so, how much?
Spyre Therapeutics Inc(SYRE) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1